Company profilePharmaceutical#160 of 1,318 in Pakistan✓ No DRAP alerts

Paramount Pharmaceuticals (Pvt) Ltd.

Pharmaceutical company · 108 brands · 131 molecules

Ranked #19 of 311 companies in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)

108 registered products 42 pharmaceutical brands 131 distinct molecules 0 DRAP alerts

Company overview

108
registered products
42
pharmaceutical brands
131
distinct molecules
12
therapeutic classes
0
DRAP alerts

Paramount Pharmaceuticals (Pvt) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 108 product registrations across 131 distinct molecules. It is the 160th largest registrant in Pakistan by product count, and ranks 19th of 311 in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord). Its portfolio is concentrated in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) and Quinolone Antibacterials. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Paramount

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Top molecules by brand count

Therapeutic classes

Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 8Quinolone Antibacterials · 7Other Beta-Lactam, Cephalosporins & Penems · 6Antiemetics & Antinauseants · 4Antiinflammatory And Antirheumatic Products · 4Antihistamines For Systemic Use · 4Lipid Modifying Agents · 3Antianemic, Iron Preparations · 3Antidepressants · 3Antiepileptics · 2Angiotensin-Ii Antagonists, Combinations · 2Drugs For Obstructive Airway Diseases, Systemic · 2

Conditions treated

High Cholestrol · 1General Infections · 1

Price band (DRAP official ceilings)

Registered products priced by source
DVAGO1 products · Rs 332.6 – Rs 332.6
Servaid2 products · Rs 223.08 – Rs 290
Median across source: Rs 332.6

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Wilshire Laboratories (Private) Limited holds 133 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxicillinAmoxycillin
ENGLISH PHARMACEUTICALS INDUSTRIES holds 71 molecules not in this portfolio
000 I.UAmikacinAmoxicillinAmoxicillin BaseAmoxycillin BaseAmpicillin
Albro Pharmaceuticals holds 21 molecules not in this portfolio
AdapaleneAdapleneBetamethasoneClindamycinClioquinolDesloratadine

Get the full profile for Paramount

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.